FIELD: pharmaceuticals.
SUBSTANCE: invention relates to novel compounds of formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R14, A and n are as defined in the claim .Invention also relates to a method for preparing them and to pharmaceutical compositions containing them.
EFFECT: compounds of the present invention have very valuable pharmacological characteristics in the field of apoptosis and oncology; apoptosis, or programmed cell death, is a physiological process, which is crucial for embryonic development and maintenance of tissue homeostasis.
28 cl, 82 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL AMINO ACID DERIVATIVES, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2016 |
|
RU2747673C2 |
| NOVEL THIENO-PYRIMIDINE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2014 |
|
RU2605403C2 |
| NOVEL HYDROXY-ESTER DERIVATIVES, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2016 |
|
RU2734418C2 |
| NEW BICYCLIC DERIVATIVES, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2016 |
|
RU2760554C1 |
| NOVEL AMMONIUM DERIVATIVES, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2016 |
|
RU2743098C2 |
| COMBINATION OF AN MCL-1 INHIBITOR AND A STANDARD DRUG FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | 2018 |
|
RU2792057C2 |
| COMBINATION OF MCL-1 INHIBITOR AND TAXANE COMPOUND, THEIR APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2763544C2 |
| COMBINATION OF MCL-1 INHIBITOR AND MIDOSTAURIN, ITS APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS | 2019 |
|
RU2818453C2 |
| LIPOSOMAL DRUG FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASM | 2017 |
|
RU2756755C2 |
| COMBINATION OF BCL-2 INHIBITOR AND MCL-1 INHIBITOR, USE AND PHARMACEUTICAL COMPOSITIONS THEREOF | 2017 |
|
RU2746705C2 |
